Browsing by Author "Macherla, Shravanti"
-
Association of Extended Dosing Intervals or Delays in Pembrolizumab-Based Regimens With Survival Outcomes in Advanced Non-small-cell Lung Cancer
Bulumulle, Anushi; Brody, Heather; Macherla, Shravanti; Walker, Paul R.; Sehgal, Kartik; Gill, Ritu R.; Qilleri, Aleksandra; McDonald, Danielle C.; Cherry, Cynthia R.; Shea, Meghan; Huberman, Mark S.; VanderLaan, Paul A.; Weiss, Glen J.; Costa, Daniel B.; Rangachari, Deepa (2021) -
Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Nonesmall-cell Lung Cancer
Bulumulle, Anushi; Brody, Heather; Macherla, Shravanti; Walker, Paul R.; Sehgal, Kartik; Gill, Ritu R.; Qilleri, Aleksandra; McDonald, Danielle C.; Cherry, Cynthia R.; Shea, Meghan; Huberman, Mark S.; VanderLaan, Paul A.; Weiss, Glen J.; Costa, Daniel B.; Rangachari, Deepa (2021) -
Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer
Macherla, Shravanti; Laks, Shachar; Naqash, Abdul Rafeh; Bulumulle, Anushi; Zervos, Emmanuel; Muzaffar, Mahvish (2018-11-07)Immune checkpoint blockade (ICB) with programmed cell death protein-1(PD-1)/programmed death ligand -1(PD-L1) antibodies has revolutionized the management of several cancers, especially non-small cell lung cancer, melanoma, ... -
Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition
Naqash, Abdul Rafeh; Appah, Ebenezer; Yang, Li V.; Muzaffar, Mahvish; Marie, Mona A.; Mccallen, Justin D.; Macherla, Shravanti; Liles, Darla; Walker, Paul R. (2019-07-05)Background Compared to conventional chemotherapy, Immune checkpoint inhibitors (ICI) are known to have a distinct toxicity profile commonly identified as immune-related adverse events (irAEs). These irAEs that are believed ...